Dear Nicole

Thank you for your patience and understanding for our delay in responding. Please find below our brief comments.

Thank you for the opportunity to comment on the AC document relating to the appraisal of obinutuzumab in combination with chlorambucil in CLL.

We would like to suggest, in order to avoid any confusion and in line with the licensed indication, that unless being compared directly as monotherapy to other single agent anti CD20 immunotherapies such as rituximab or ofatumumab, NICE and the ERG should refer to obinutuzumab throughout the text as obinutuzumab- chlorambucil.

The standard practice in haemtaology is for a CD20 monoclonal antibody to be combined with a chemotherapy "backbone".

The standard therapies used as the chemo backbone in the treatment of CLL are chlorambucil, bendamustine and fludarabine with or without cyclophosphamide.

The comparator anti CD20 antibodies used in conjunction with the above chemotherapy agents are rituximab and ofatumumab.

Therefore it would be illogical and highly unlikely that the monoclonal antibody obinutuzumab as a single agent would ever be compared to bendamustine, or any other cytotoxic chemotherapy directly. Indeed, rituximab monotherapy as a front line treatment is rarely, if ever used.

Kind regards

[redacted]